Ispire Technology Inc. ISPR reported its first quarter financial results on Tuesday, revealing a 59.1% year-over-year increase in revenue to $42.9 million in the three months ended Sept. 30, 2023.
Cannabis vaping products contributed $17.3 million to revenue during the fiscal first quarter of 2024, up by 116.8% year-over-year, while tobacco vaping products contributed $25.5 million, representing a 34.8% year-over-year increase.
"We remain confident in our ability to maintain our position as the leading premier precision dosing technology company as we've not only secured our position in existing markets but have also made inroads into new geographies, adapting swiftly to increased market demands,” Michael Wang, co-chief executive officer of Ispire said.
Q1 2024 Financial Highlights
- Gross profit totaled $6.9 million, up from $4.8 million in the same period of last year.
- Gross margin decreased to 16.1% as compared to 17.8% in the same period of 2023.
- Net loss amounted to $1.38 million, down from $2 million in the same quarter of fiscal 2023.
- Loss from operations was $911,273, down from $1.2 million in the prior year’s period.
- Total operating expenses increased 29.8% to $7.8 million as compared to $6 million in the same period of 2023.
- As of Sept. 30, 2023, the company had $88.4 million in total assets.
ISPR Price Action
Ispire’s shares traded 2.96% higher at $11.12 per share during the pre-market session on Tuesday morning.
Related News
- Snoop Dogg's 'Dogg Lbs' Goes Global With Aspire-Hempacco North America Distribution Deal
- ISPIRE CEO Says Manufactured Cannabis Products Have Gained Traction And Customers
- Publicly-Traded Vape-Tech Company Posts 100.4% YoY Growth In Revenue For Pot Products
Photo: Courtesy of Testeur de CBD on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.